Shares of MaxCyte, Inc. (LON:MXCT - Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 188.17 ($2.55) and traded as low as GBX 162.10 ($2.19). MaxCyte shares last traded at GBX 162.18 ($2.19), with a volume of 3,016 shares trading hands.
MaxCyte Price Performance
The business has a fifty day moving average price of GBX 185.41 and a two-hundred day moving average price of GBX 267.62. The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38. The firm has a market capitalization of £219.79 million, a price-to-earnings ratio of -6.10 and a beta of 1.13.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Further Reading
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
